The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2015

Filed:

Jul. 24, 2012
Applicants:

Baranyai Zsolt, Debrecen, HU;

Ernö Brücher, Debrecen, HU;

Simona Bussi, Vercelli, IT;

Alessandro Maiocchi, Monza, IT;

Fulvio Uggeri, Codogno, IT;

Inventors:

Baranyai Zsolt, Debrecen, HU;

Ernö Brücher, Debrecen, HU;

Simona Bussi, Vercelli, IT;

Alessandro Maiocchi, Monza, IT;

Fulvio Uggeri, Codogno, IT;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); A61K 31/28 (2006.01); A61K 31/4172 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4172 (2013.01); A61K 31/28 (2013.01);
Abstract

The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity associated to free Gd3+, deriving from GDBCA, is prevented by oral administration of L-histidine before administration of the contrast agent. A method for the prevention of toxic metal accumulation which consists in the administration, preferably by the oral route, of L-Histidine is also disclosed. L-Histidine is preferably administered as a single oral dose comprised from 0.2-20 g.


Find Patent Forward Citations

Loading…